Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.4K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

10.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
10.0K
Master Transcription Regulators02:23

Master Transcription Regulators

6.8K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.0K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Intelligence level and structure in school age children with fetal growth restriction].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics·2009
Same author

Uncoupling the D1-N-methyl-D-aspartate (NMDA) receptor complex promotes NMDA-dependent long-term potentiation and working memory.

Biological psychiatry·2009
Same author

A phospho-directed macroporous alumina-silica nanoreactor with multi-functions.

ACS nano·2009
Same author

Subintimal angioplasty for below-the-ankle arterial occlusions in diabetic patients with chronic critical limb ischemia.

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists·2009
Same author

Natural killer/T cell lymphoma initiating with pleural effusion: the significance of MICM combined techniques for the diagnosis.

Zhongguo shi yan xue ye xue za zhi·2009
Same author

[Advance of study on animal models of lymphoma].

Zhongguo shi yan xue ye xue za zhi·2009

Related Experiment Video

Updated: May 23, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

817

KRM2 promotes renal cell carcinoma progression and inhibits ferroptosis by interacting with ATF2.

Fang Liu1, Mengtong Wang2, Gao Li2

  • 1Department of Nephrology & Rheumatology and Immunology, Beijing Chao-Yang Hospital/Capital Medical University, Beijing, 100043, China.

Experimental Cell Research
|March 8, 2025
PubMed
Summary
This summary is machine-generated.

Kringle-containing transmembrane protein 2 (KRM2) promotes renal cell carcinoma (RCC) progression. KRM2 enhances tumor growth, proliferation, migration, and inhibits apoptosis and ferroptosis by regulating ATF2 in RCC.

Keywords:
ATF2FerroptosisKRM2Renal cell carcinoma

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.6K
Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.1K

Related Experiment Videos

Last Updated: May 23, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

817
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.6K
Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The function of kringle-containing transmembrane protein 2 (KRM2) in renal cell carcinoma (RCC) is not well understood.
  • Investigating KRM2's role is crucial for understanding RCC pathogenesis.

Purpose of the Study:

  • To elucidate the mechanistic role of KRM2 in regulating RCC progression.
  • To determine the relationship between KRM2 expression and clinical features of RCC.

Main Methods:

  • KRM2 expression analysis using tissue microarrays in RCC tissues.
  • In vitro studies involving KRM2 and ATF2 knockdown/overexpression in RCC cell lines.
  • In vivo tumor xenograft models in nude mice.
  • Gene expression microarray, co-immunoprecipitation, and cycloheximide pulse-chase assays to identify downstream targets.

Main Results:

  • KRM2 expression is significantly elevated in RCC tissues and correlates with tumor size, grade, stage, infiltration, and patient age.
  • Inhibition of KRM2 suppressed tumor growth, proliferation, migration, and promoted apoptosis and ferroptosis in RCC.
  • KRM2 positively regulates ATF2 expression, and ATF2 knockdown reversed KRM2's oncogenic effects.

Conclusions:

  • KRM2 acts as an oncogene in RCC, promoting tumor progression and ferroptosis.
  • KRM2 exerts its effects by regulating its downstream target, ATF2.